Patient-reported outcomes (PROs) from the LAURA study: Osimertinib (osi) in patients with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) without progression after definitive chemoradiotherapy (CRT)

Category Systematic review
ConferenceEuropean Lung Cancer Congress (ELCC) 2025
Year 2025
This article has no abstract
Epistemonikos ID: 191455a8d5fa2b297ce0f25e173f0197af393f16
First added on: Jan 22, 2026